Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma

Many efforts are underway to develop novel therapies against the aggressive high-grade serous ovarian cancers (HGSOCs), while our understanding of treatment options for low-grade (LGSOC) or mucinous (MUCOC) of ovarian malignancies is not developing as well. We describe here a functional precision on...

Descripción completa

Detalles Bibliográficos
Autores principales: Murumägi, Astrid, Ungureanu, Daniela, Khan, Suleiman, Arjama, Mariliina, Välimäki, Katja, Ianevski, Aleksandr, Ianevski, Philipp, Bergström, Rebecka, Dini, Alice, Kanerva, Anna, Koivisto-Korander, Riitta, Tapper, Johanna, Lassus, Heini, Loukovaara, Mikko, Mägi, Andrus, Hirasawa, Akira, Aoki, Daisuke, Pietiäinen, Vilja, Pellinen, Teijo, Bützow, Ralf, Aittokallio, Tero, Kallioniemi, Olli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938120/
https://www.ncbi.nlm.nih.gov/pubmed/36476658
http://dx.doi.org/10.1038/s41416-022-02067-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938120/
https://www.ncbi.nlm.nih.gov/pubmed/36476658
http://dx.doi.org/10.1038/s41416-022-02067-z

Ejemplares similares